Exosome-Based Liquid Biopsy Platform Technology Solution
- Founded in 2015
- $8 million in grants and private funding
- Validated in over 350 clinical human samples
- 8 peer-reviewed publications
- 4 patents issued and pending
- Experienced leadership and advisory team
Chip Diagnostics is commercializing an innovative hardware and data/AI informatics platform, used to develop novel, exosome-based biomarker signatures for early disease diagnostics and therapy management.
We developed a proprietary workflow to rapidly scan blood samples for trillions of exosomes individually to identify and interpret organ-specific exosome populations.
Our solutions enable extremely accurate “fingerprinting” of a broad range of diseases and their states, offering inexpensive, and less time and resource-intensive workflows across biopharma/drug discovery and diagnostics use cases.
Disease Indications – Human Studies
We are in the pre-commercial stage with our exosome-based assays for pancreatic cancer and traumatic brain injury, and in
development – under commercial sponsorship – with an innovative lung cancer diagnosis and therapy response signature panel. Click here for more information.
Opportunity for Liquid Biopsies
1 $28.8 billion market opportunity
Potential Impact of Early Diagnosis
2 U.S. lung cancer five-year survival rate
2 If diagnosed at an earlier stage rises to
2 Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: A decision and cost-effectiveness analysis. J Am Med Assoc. 2003;289(3):313-322. doi:10.1001/jama.289.3.313